Storia in 4 fonti

FDA Finally OKs Twice-Rejected Melanoma Drug

Approved in combination with nivolumab for patients who progress on prior anti-PD-1 therapy

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo5 g fa

FDA Finally OKs Twice-Rejected Melanoma Drug

Approved in combination with nivolumab for patients who progress on prior anti-PD-1 therapy

originale

healio.com4 g fa

FDA OKs accelerated approval to twice-rejected Tudriqev with Opdivo for advanced melanoma

The FDA has granted accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who experienced disease progression with a prior…

Leggi questa versione → originale

Timeline cronologica

giovedì 6 agosto 2026·biopharmadive.com
Replimune rebounds to win FDA approval of melanoma drug
The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.
giovedì 6 agosto 2026·medpagetoday.com
FDA Finally OKs Twice-Rejected Melanoma Drug
Approved in combination with nivolumab for patients who progress on prior anti-PD-1 therapy

FDA Finally OKs Twice-Rejected Melanoma Drug

Confronto fonti

FDA Finally OKs Twice-Rejected Melanoma Drug

FDA OKs accelerated approval to twice-rejected Tudriqev with Opdivo for advanced melanoma

Timeline cronologica

Replimune rebounds to win FDA approval of melanoma drug

FDA Finally OKs Twice-Rejected Melanoma Drug

Replimune melanoma drug snags coveted FDA approval after yearlong clash, two rejections

Replimune rebounds to win FDA approval of melanoma drug

Replimune melanoma drug snags coveted FDA approval after yearlong clash, two rejections

FDA OKs accelerated approval to twice-rejected Tudriqev with Opdivo for advanced melanoma